We performed a post hoc analysis using real-world data from the REal worlD Effectiveness and Safety of mepolizumab (REDES) study (7), which included patients with severe eosinophilic asthma who were treated with mepolizumab (anti-IL-5 monoclonal antibody) (8) for 1 year, and applied our two composite clinical remission definitions (OCS-free; exacerbation-free; asthma control test (ACT) score ≥20; and with or without post-bronchodilator FEV1 ≥80%). Here, IL5 is linked to asthma.